GALT
Galectin Therapeutics Inc
NASDAQ: GALT · HEALTHCARE · BIOTECHNOLOGY
$2.27
+0.89% today
Updated 2026-04-30
Market cap
$156.01M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.48
Dividend yield
—
52W range
$1 – $7
Volume
0.3M
Galectin Therapeutics Inc (GALT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-3,728.00%
ROA
-67.80%
Debt/equity
-0.98x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-3.19M | — | — | — |
| 2007 | — | $-9.43M | — | — | — |
| 2008 | — | $-3.15M | — | — | — |
| 2009 | — | $-7.46M | — | — | — |
| 2010 | — | $-5.63M | — | — | — |
| 2011 | $0.00 | $-10.91M | — | — | — |
| 2012 | $0.00 | $-9.68M | — | — | — |
| 2013 | $0.00 | $-12.09M | — | — | — |
| 2014 | $0.00 | $-15.79M | — | — | — |
| 2015 | $0.00 | $-20.03M | — | — | — |
| 2016 | $0.00 | $-21.44M | — | — | — |
| 2017 | $0.00 | $-16.23M | — | — | — |
| 2018 | $0.00 | $-13.90M | — | — | — |
| 2019 | $0.00 | $-13.29M | — | — | — |
| 2020 | $0.00 | $-23.46M | — | — | — |
| 2021 | $0.00 | $-30.53M | — | — | — |
| 2022 | $0.00 | $-38.78M | — | — | — |
| 2023 | $0.00 | $-41.07M | — | — | — |
| 2024 | $0.00 | $-47.05M | — | — | — |
| 2025 | $0.00 | $-30.84M | — | — | — |